Delisting risk
SXTP · NASDAQ · Biotechnology

60 Degrees Pharmaceuticals (SXTP)

Develops and markets tafenoquine medicines for malaria prevention and vector-borne diseases.

$0.9600
Pre-market−0.01 (−1.02%)
At close$0.9699(−4.91%)

Something off on this page? Send us feedback.

Next report
Nov 12, 2026
estimated · in 70 days
EPS estimate
−$0.61
Revenue estimate
$270.0K
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$14.20−$1.56−$1.25−$2.64−$1.69−$1.28−$0.90Pending
Estimate−$4.01−$1.31−$1.24−$1.84−$2.28−$0.76−$0.74−$0.61
Surprise−254.1%−19.1%−0.8%−43.5%+25.9%−68.4%−21.6%

RevenueReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$261.4K$163.6K$100.9K$437.6K$310.0K$230.0K$207.9KPending
Estimate$250.0K$300.0K$150.0K$200.0K$320.0K$435.0K$185.0K$270.0K
Surprise+4.6%−45.5%−32.7%+118.8%−3.1%−47.1%+12.4%

History

DateEstimateReportedSurprise
Nov 2026−$0.61
Aug 2026−$0.74−$0.90−21.6%
May 2026−$0.76−$1.28−68.4%
Mar 2026−$2.28−$1.69+25.9%
Nov 2025−$1.84−$2.64−43.5%

The latest year is open to everyone — the 16 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Apr 2024
Nov 2023
Aug 2023
Jun 2023
Mar 2023
Dec 2022
Sep 2022
Jun 2022
Mar 2022
Dec 2021
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 12, 2026−$0.61$270.0K
Aug 14, 2026−$0.74−$0.90−21.6%$185.0K$207.9K+12.4%+1.7%
May 15, 2026−$0.76−$1.28−68.4%$435.0K$230.0K−47.1%+3.6%
Mar 26, 2026−$2.28−$1.69+25.9%$320.0K$310.0K−3.1%+0.7%
Nov 13, 2025−$1.84−$2.64−43.5%$200.0K$437.6K+118.8%−22.2%

The latest year is open to everyone — the 16 quarters behind it read with an account.

Sign in
Aug 13, 2025
May 15, 2025
Mar 27, 2025
Nov 14, 2024
Aug 14, 2024
May 15, 2024
Apr 1, 2024
Nov 20, 2023
Aug 25, 2023
Jun 8, 2023
Mar 31, 2023
Dec 31, 2022
Sep 30, 2022
Jun 30, 2022
Mar 31, 2022
Dec 31, 2021